A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.
TTVR plus optimal medical therapy yields greater improvement in disease-specific and general health status than OMT alone. HealthDay News — For patients with symptomatic and severe or greater ...